#cannabisaficionado

Industry Innovators

Jade Proudman: On a Mission to Break Down Barriers

Published

on

Jade Proudman
Advertisement Back2Grow Advertisement

More than 1.3 million people use CBD on a regular basis in the U.K. Jade Proudman is working tirelessly to bring access, and education to those consumers in England and beyond.

CBD oil is sold legally in the U.K, according to the Centre for Medicinal Cannabis (CMC), a nonprofit organization dedicated to research, policy and education.

A study recently conducted by the CMC found that therapeutic use of the cannabinoid is growing rapidly; “The U.K. CBD market is currently growing at double digits and expected to be just short of £1B in 2025. This would be equivalent to the entire U.K. herbal supplement market in 2016.”

But, many of the cannabis-based products on the market aren’t all they are cracked up to be.

In the same CMC report, researchers tested 30 different CBD products available on the market. They found only 11/29 had within 10% of the advertised CBD content. Another 11 products (38%) “actually had less than 50% of the advertised CBD content. One product had 0% CBD,” the CMC concludes.

The results expose regulatory gaps in the CBD market. Jade Proudman, a champion for premium products, transparent brands, and educating the European marketplace about cannabinoids, is an advocate of the work being carried out by the CMC.

Proudman and her husband, Leslie, founded Savage Cabbage in 2016. The storefront in North Yorkshire draws visitors from all over the U.K. to sit on the L-shaped couch for a cuppa and cannabinoid-chat.

 

View this post on Instagram

 

Savage cabbage HQ 🌴🌴

A post shared by SavageCabbageLtd (@savagecabbageltd) on

“As you walk in, the first thing you see is our beautiful seating area which does encourage people to take a seat and enter into conversation with us, enabling questions to be asked and answered,” says Proudman. The shop often hosts discussion panels or events like cannabinoid awareness sessions and open house coffee mornings.

Savage Cabbage has become well known for such services, which are free.

“I’m proud of that element that we achieved,” she says. “This is not about a sales transaction – it’s about people improving their own wellness through natural means and education.”

This is Proudman’s ethos; she’s a problem solver who is not driven by the bottom dollar, but by the need to share her story in order to help others.

Savage Cabbage is an official U.K./E.U. retailer of Myriam’s Hope, and Charlotte’s Web whole-plant hemp extracts — the same product that changed Proudman’s life.

In 2012, Proudman fell “very sick, very quickly,” she says. “My entire life changed in a very few short space of time. I ended up in a hospital fighting for my life.”

Proudman suffers from fibromyalgia and spinal myoclonus epilepsy, bowel disease, in addition to a host of other conditions, which once left her bedridden, and reliant on medications including morphine.

“I was very much dependent on pharmaceutical options to exist because I couldn’t manage,” she explains. “I spent a year in and out of hospitals. I had 10 very big surgeries, and had some internal organs removed.”

Proudman’s health struggles left her housebound and with permanent disabilities — it also cost her her job with Children and Young People’s services in North Yorkshire.

She became depressed. “I just didn’t want to be here anymore.”

Little did Proudman know, her life was about to take another drastic change.

One night, Proudman and her husband — who she credits for keeping her going — watched the CNN documentary, Weed, with Sunjay Gupta. That was Proudman’s first introduction to Charlotte’s Web.

The film follows the stories of patients including Charlotte Figi. “Charlotte suffered from a severe form of epilepsy called Dravet’s Syndrome. She suffered over 300 grand mal seizures a day and by the age of five had failed all pharmaceutical options,” according to CW Hemp, and the Stanely Brothers, who developed the now globally sought-after strain.

“The Charlotte’s Web products were created for her, her seizures have since drastically reduced, quality of life has improved, and the rest is documented history,” adds the Stanely Brothers’ site.

Because Proudman also suffers seizures, she wondered whether CBD oil “could help me in any shape or form.” Although it wasn’t easy — they managed to acquire some CW Hemp Oil. Within 48 hours of using it for the first time, Proudman was morphine free.

“At the time, I didn’t know how it worked or why it worked, or what the endocannabinoid system (ECS) was… any of those things.” she says, “I took a very steep learning journey.”

Today, Proudman is a prominent advocate for CBD in the U.K. Her company reaches customers in approximately 60 different countries.

Proudman no longer takes any pharmaceutical medications. “I stopped 14 different medications — I just use my CBD and a host of other vitamins and minerals.”

“That’s how Savage Cabbage came to be,” Proudman says, “I knew there were other people like me who felt lost, who felt really kind of is this it? Is this my only option?”

“When I started this, I had no idea really what I’d be doing… I just knew I needed to speak to people and help people get ahold of something that was difficult to get ahold of,” she explains. “That brought its own challenges which I worked through,” by building a strong relationship with CW Hemp, and eventually, Myriams’s Hope — the two products she uses.

 

View this post on Instagram

 

#SpreadTheLoveTour #2018#WhyCW #betterthancbd

A post shared by SavageCabbageLtd (@savagecabbageltd) on

“I never came into this space as an advocate for cannabis,” she explains, “I always thought drugs were bad. As soon as I discovered the health that I had so desperately missed for so many years, I was like… I get it now.”

That gave her the drive to tackle negatives and misconceptions head-on. “I come from a place of understanding. I can relate to people who are scared, who think this is a drug… I once felt the same way,” she says.

She is the first to admit that she isn’t a medical expert. This us why the Savage Cabbage team guides customers to organizations like the Realm of Caring, a nonprofit committed to research.

Proudman knows the industry is plagued with misinformation and questionable businesses that prey on patients in need for the sake of a sale.

“There have been a lot of times when I’ve been at a show, and someone will come to me and say, “I’ve got this problem, and I got this product off the internet. It makes me feel a little bit sick, but I’ve been told it’s good for me,” Proudman explains.

She keeps an “amnesty” bin handy for these instances. ”I just let people throw their stuff in if they don’t know exactly where it came from, what’s in it, or haven’t got a certificate of analysis.”

Proudman will, in turn, swap their product for a certified brand. “I say, let’s try something of quality, and If you feel a positive effect from that, then let’s have a conversation, and see how we can help you,” Proudman explains. “If somebody makes something rubbish in their bathtub, shoves it into a bottle and gives it to somebody,” it can cause a bad experience, and turn someone off from CBD altogether.

“It’s all about the source, origin, and quality,” Proudman adds, ”If you’re helping someone with the learning experience, they become a really big ambassador of their own.”

Her approach is holistic and based on a style of shared or joint learning — a topic in which Proudman earned a Master’s degree in.

Proudman works with legislative and regulatory bodies, including the CMC, to advocate for research and education for the millions of consumers in the U.K.

She is a representative member of the CMC, this membership allows her to discuss and create ideas with other industry leaders.

The CMC works with government and nongovernment agencies to build a regulatory framework for the medical cannabis and CBD industries. The organization recently joined forces with the award-winning consultancy group Global Regulatory Services (GRS) to develop the framework needed for the U.K. government, and the European Food Safety Authority (EFSA).

The EFSA recently classified cannabinoids as “novel foods,” or foods “that had not been consumed to a significant degree by humans in the EU before 15 May 1997.” The classification requires foods containing CBD to meet certain standards to be fully legal.

Although reactions to the classification of cannabinoids as novel foods are mixed, Proudman believes it’s a positive step toward ensuring quality access.

There are millions of registered daily users of CBD in this country, Proudman explains. “That’s a significant portion of our population. It will only get bigger. It would be nice to see a regulated, accessible, professional industry that can spend money on [awareness] so we can start educating the populous.”

Proudman has made major strides in access to CBD for U.K. residents. As she moves forward, she will pass the torch to her team at Savage Cabbage, and resign her role as CEO of the company by year’s end.

She’ll transition into her new role ‘Brand Advisor and Consultancy’. The position will allow her to expand her reach and continue to advocate for the same products that changed her life.

Industry Innovators

Auxly’s Cannabis Sales Rise as Last Year’s One-Time Gain Complicates the Profit Comparison

The Canadian cannabis producer’s revenue and operating cash figures improved, while its headline net-income comparison tells a different story.

Published

on

An aisle between warehouse racks filled with cardboard boxes

Auxly’s third-quarter cannabis results offer two headlines that need to be read together. Net revenue increased 24 percent from a year earlier to C$49.5 million, while reported net income declined. The difference does not mean the sales growth disappeared; it reflects, in part, a comparison with a prior-year quarter containing a substantial one-time gain.

The Canadian cannabis producer released its results November 12, 2026 for the three months ended September 30. Its accompanying financial statements and management discussion are dated November 11. Amounts here are Canadian dollars, avoiding a misleading comparison with U.S.-dollar figures reported by other cannabis companies.

Sales growth and the profit comparison

Auxly’s news release reports adjusted EBITDA of C$15.8 million, up 29 percent, and net income of C$13.6 million, compared with C$20.5 million a year earlier. Management notes that the 2025 comparison included a C$8.1 million after-tax gain related to the Imperial debenture settlement.

That creates a reason to examine the components of earnings rather than selecting whichever headline looks most dramatic. A settlement gain can raise reported profit without representing repeatable sales of cannabis. Conversely, removing selected items produces a different measure whose definition and reconciliation still need to be understood.

Adjusted EBITDA is not the same as net income, and neither is simply the amount of cash available for expansion. Auxly identifies adjusted EBITDA as a non-GAAP measure and directs readers to its reconciliation. The useful comparison is between consistently defined measures over time, with the excluded items visible.

The financial statements add a cash distinction

The interim statements report C$14.3 million of net cash provided by operating activities during the quarter. That differs from the C$14.8 million figure before working-capital changes highlighted in the announcement. Both can be accurate because they describe different stages of the cash-flow calculation.

Working capital includes movements in items such as receivables and inventory. A measure calculated before those movements helps isolate one aspect of performance, but it cannot answer every question about cash actually generated during the period. The statements provide the bridge between the two numbers.

At September 30, the statements show C$51.4 million in cash and cash equivalents. That is a balance at a particular date. It should not be confused with the quarter’s revenue, its net income or a promise that the entire balance will be spent on new production.

The statements also label the interim figures unaudited and explain that share and per-share amounts reflect the July 28 share consolidation. Those details matter when comparing old share counts or earnings per share, even though they do not change the basic story about cannabis sales.

Flower and pre-rolls remain central

The management discussion says dried flower and pre-roll products accounted for approximately 64 percent of quarterly net revenue, with the balance from the company’s other cannabis product categories. It attributes year-over-year sales growth to higher volumes across core products and improved flower pricing, partly offset by pressure on vape prices.

That is more informative for readers following the cannabis shelf than an undifferentiated growth percentage. Different formats can move in different directions at the same company. Higher total revenue does not establish that every product category gained pricing power or that every retailer saw the same demand.

The filing also describes the role of Auxly Leamington in cultivation and processing. An integrated production footprint can support supply, but its existence alone does not demonstrate consumer preference, product quality or a future sales result. Those claims require evidence beyond the size of a facility.

The previous quarter supplies context

Auxly’s August 13 second-quarter announcement reported C$45.8 million in net revenue and C$14.3 million in adjusted EBITDA. The third-quarter figures are higher than those earlier results, as well as higher than the year-earlier revenue and adjusted EBITDA comparisons. That is a useful check on the direction of the reported business.

Quarter-to-quarter changes are still different from a sustained trend. Product launches, customer ordering and seasonal patterns can affect individual periods. A single quarter does not establish the eventual return on a capital project or the success of an export strategy.

Our earlier coverage of Weedmaps’ tougher advertising quarter illustrated another part of the cannabis economy. The companies have different business models and reporting measures, so their results should not be treated as interchangeable signals for the whole industry.

For Auxly, the next useful tests are continued demand, cash generation after working-capital movements and the results of planned investments. The present filing supports a specific conclusion: cannabis revenue and several operating indicators improved, while the reported net-income comparison requires attention to last year’s exceptional items.

Illustrative warehouse stock photograph; not an Auxly facility or identified cannabis inventory. Photo: Russ Murray / Unsplash.

Continue Reading

Cannabis

Charlotte’s Web Reports Lower CBD Sales but a Narrower Quarterly Operating Loss

The hemp-derived CBD company’s latest results show why lower revenue and an improving quarterly loss can coexist—and why neither resolves the policy outlook.

Published

on

Empty amber glass bottles arranged on a light surface

Charlotte’s Web reported a difficult sales quarter for its hemp-derived CBD business while narrowing its operating loss. Revenue for the three months ended September 30, 2026 was US$9.4 million, down 18.3 percent from a year earlier. Its operating loss narrowed to US$3.7 million from US$5.3 million, showing why the direction of sales and the direction of a loss do not always match.

The company announced the results November 12 and filed its quarterly report with the U.S. Securities and Exchange Commission. The release attributes weaker revenue primarily to California restrictions that took effect in July, reduced promotional discounting and softer demand in parts of the hemp-wellness market. Those explanations are management’s account of the quarter, rather than an independent measurement of every factor affecting CBD shoppers.

Less revenue does not automatically mean a larger loss

The company’s earnings release reports quarterly gross profit of about US$4.4 million, compared with US$4.5 million a year earlier, even as sales fell. Gross margin improved to 46.9 percent from 38.9 percent. Selling, general and administrative expenses declined to US$8.1 million from US$9.7 million.

A percentage margin and a dollar profit measure answer different questions. A company can retain a larger share of each sales dollar while bringing in fewer dollars overall. Lower expenses can then narrow the operating loss without putting the business into operating profit. That is the distinction these results require.

The announcement also identifies an inventory reserve linked to simplifying the product range. Readers should therefore resist interpreting a single margin percentage as a permanent new baseline. Product mix, pricing, manufacturing costs and inventory adjustments can all affect the calculation.

The quarterly filing keeps the periods straight

The Form 10-Q records quarterly revenue more precisely at US$9.393 million and a net loss of US$3.458 million. These rounded to the US$9.4 million revenue and US$3.5 million net loss in the announcement. An operating loss and a net loss are different lines of the accounts, not conflicting reports of one number.

The nine-month picture is also distinct from the latest quarter. The release reports a US$20.7 million net loss for the first nine months, including noncash items associated with the earlier debenture conversion. It would be misleading to describe an improved third-quarter operating loss as proof that every year-to-date earnings measure improved.

The filing shows US$11.364 million of cash and cash equivalents at September 30. Cash on that date is a financial-position measure, rather than sales or profit earned during the quarter. Looking at the income statement and cash-flow statement together gives a fuller picture than treating a positive cash balance as evidence of profitability.

Hemp policy remains part of the business story

Cannabis policy is directly relevant to this CBD company because the legal definition of hemp determines which products can use that route to market. The Congressional Research Service’s October 28 legal sidebar explains that the federal delay does not move every element of the new definition to the same date. It distinguishes the treatment of certain cannabinoids not naturally produced by the plant from provisions delayed until December 11.

That distinction is useful beyond one company. A hemp-derived label does not settle a product’s future legal status, and a federal deadline does not automatically override a state’s separate rules. Consumers and businesses need to identify the applicable product definition, ingredients and jurisdiction.

Charlotte’s Web’s October 28 announcement said it planned to hold a corporate update after December 11 rather than a November earnings call, seeking greater policy clarity before discussing its outlook. That is a communications plan, not evidence that Congress will produce the outcome the company prefers.

Product access and medical evidence are separate

A financial report from a CBD business does not establish that a product treats a disease or is appropriate for a particular person. Sales trends describe commercial activity. They do not measure a clinical benefit, and a discussion of future healthcare distribution should not be mistaken for a new drug approval or a general reimbursement entitlement.

Our coverage of Willie Nelson’s hemp-policy appeal addresses the public debate over access. Charlotte’s Web’s results supply a different perspective: how a company says restrictions, pricing decisions and expenses are affecting its accounts. The two stories illuminate different parts of the same policy uncertainty.

The next meaningful business signals will include the durability of any sales recovery, spending levels and the details of the legal framework actually in force. For now, the results show a smaller quarterly operating loss alongside lower CBD revenue. They do not yet resolve whether the company can turn that improvement into sustained growth and profitability.

Illustrative empty-bottle stock photograph; not Charlotte’s Web packaging or identified CBD products. Photo: Kelly Sikkema / Unsplash.

Continue Reading

Industry Innovators

Portland Weighs Cannabis Pickup Windows and Licensing Payment Changes

Portland’s cannabis pickup-window and licensing proposal remains under review, with the city record listing a December 8 committee meeting.

Published

on

Portland waterfront buildings seen across the river

Portland is considering removing a city-code restriction on cannabis drive-through and walk-up sales, but the proposal has not become a new retail permission. The city’s record for Ordinance 2026-407 shows the November 10 City Life Committee item was continued, with December 8 listed as its next meeting date.

The proposal introduced by Mayor Keith Wilson combines two subjects: updating the language governing exterior sales windows and revising the way licensing-payment provisions appear in city code. For cannabis shoppers, the first is about how a purchase might be collected. For operators, the second concerns the timing and administration of license costs.

A retailer considering a physical alteration would still need to assess the property and any other applicable approvals. Removing one cannabis-specific sales restriction is not the same thing as approving a building project.

The window restriction is specific

Portland’s current marijuana licensing chapter bars sales from vendor carts, temporary structures, satellite locations and exterior openings such as drive-through facilities or walk-up windows. The proposed amendment would remove the exterior-opening language while retaining restrictions on those other kinds of sales locations.

That is narrower than allowing cannabis sales anywhere a customer can drive or walk. A licensed premises would still be a particular business location, subject to the rest of its applicable requirements. The change concerns a method of serving customers, not the disappearance of the licensing system.

City materials say the amendment would align Portland’s wording with Oregon rules that made on-site delivery a permanent option in September 2020, following temporary pandemic arrangements. That history helps explain why the debate is framed as an update to conflicting language rather than a brand-new statewide retail model.

Convenience does not mean on-site consumption

One important boundary remains in the proposed code exhibit: the provision against consumption on licensed premises is retained, with its existing narrow employee exception under Oregon law. A pickup window and a consumption lounge are different activities.

The same exhibit retains operating-hour and security requirements. Its redline shows a targeted deletion concerning sales openings, rather than an across-the-board removal of the rules governing retail premises. Reading the actual proposed changes is more informative than assuming that the phrase drive-through implies a completely different type of store.

For a customer, the practical questions would still include whether a specific retailer offers a service, how the order is handled and which rules apply. A citywide code amendment, if adopted, would not guarantee that every shop installs a window or changes its property layout.

The payment provisions affect operators differently

The ordinance also addresses the Deferred Payment Program for license fees. The city’s explanation says a 50% initial payment better supports collection and that the code should refer to the council-approved fee schedule rather than preserve outdated dollar amounts.

That is a distinction between the text of the code and the administration of a program. City materials say programmatic changes were communicated in June and July and implementation began in August. The proposal would codify practices already in place, according to the city, rather than introduce every payment change for the first time.

Operators evaluating the proposal therefore need both the amended text and the applicable fee schedule. A headline about pickup windows does not explain a business’s entire licensing bill, and an old fixed amount quoted from code may not describe current program administration.

Businesses are raising questions about cash flow

In KPTV’s November 10 reporting, Mikhala Armstrong described support for greater accessibility alongside concerns from cannabis operators about payment obligations and late fees. Those interviews add an important perspective to the city’s stated goal of improving administration.

The two views are not interchangeable. The city describes its intended program effects; individual operators describe how they believe the arrangements affect their businesses. A final assessment should distinguish those accounts from evidence about what happens after implementation.

Our coverage of Missouri’s interstate cannabis guidance concerned a separate jurisdiction, but illustrates a related point: legal cannabis markets remain governed by specific rules at different levels. A state allowance does not make every local detail irrelevant.

The next step is still a public decision

The city’s document history is the place to follow whether the committee advances or amends the proposal. As of this review, its status is continued, not adopted. Readers should check the updated agenda before relying on the December meeting listing or making plans to offer a new service.

The potential change is concrete: remove a particular restriction on how licensed cannabis stores serve customers and bring fee language into line with current administration. Whether that becomes the final city policy remains the question before Portland, rather than a decision already made.

Illustrative Portland waterfront photograph; not a dispensary or proposed pickup site. Photo: Meggyn Pomerleau / Unsplash.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.